Nonrulemaking

Requests that the FDA declare that the drug product, Edaravone Powder for Oral Suspension 105 mg/Sachet is suitable for submission in an Abbreviated New Drug Application.

🏛 Food and Drug Administration (FDA)FDA-2026-P-8832

Pharmaceutical Policy

Documents

7

Total comments

0

all analyzed

Comment status

Open

Last activity

—

In this docket

Documents

Rules, notices, and supporting material — the primary rule pinned first.

All 7 Supporting & Related Material 5 Other 2

📄 Primary document

OtherAug 7, 2026

Suitability Petition from Pharmobedient Consulting, LLC

No comment period

Other· Aug 7, 2026
Acknowledgement Letter from FDA DMB to Pharmobedient Consulting, LLC→
No comment period
Supporting & Related Material· Aug 7, 2026
Attachment 1 - Orange Book→
Supporting & Related Material· Aug 7, 2026
Attachment 2 - RLD-Labeling→
Supporting & Related Material· Aug 7, 2026
Attachment 3 - Edaravone Powder for Oral Suspension PI revision→
Supporting & Related Material· Aug 7, 2026
Attachment 3 - Edaravone Powder for Oral Suspension PI revision - Track Changes→
Supporting & Related Material· Aug 7, 2026
Attachment 4 - Draft Guidance on Edaravone→